ArticleCancer discovery2021
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 1 pooled it
18.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 1 synthesis or guideline pooled it, 270 citations in OpenAlex.
- Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception.Clinical epigenetics · 2024Pooled it
- Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.Nature communications · 2024Trial
- The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.Cancer biology & therapy · 2026Review
- Nuclear OXCT1 attenuates histone β-hydroxybutyrylation-mediated MHC-I transcription.Nature chemical biology · 2026Article
- Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- The Role of IGF2BP3-Mediated Immune Response Activation in Enhancing Immunotherapy of Koumine for Gastric Cancer.Cancer science · 2026Article
- The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma.Journal of advanced research · 2026Article
- Spatiotemporally Ultrasound-Controlled Nanoparticles Reprogramming Immunostimulatory Antigen-Presenting Cancer-Associated Fibroblasts to Enhance Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer.Nature communications · 2026Article
- Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.Nature biomedical engineering · 2026Article
- The proteomics and phosphoproteomics landscape of melanoma under T cell attack.Cell reports. Medicine · 2026Article
- LISS enables immune evasion of colorectal cancers irrespective of MSI status.Signal transduction and targeted therapy · 2026Article
- Ferroptotic tumor cells reprogram tumor-associated macrophage antigen presentation to enhance the efficacy of immune checkpoint blockade.Cell reports. Medicine · 2026Article
- Dual Role of Cancer Epithelial-Specific TRAF3 in Regulating Breast Cancer Cell Survival and Lymphocyte Activity.International journal of molecular sciences · 2026Article
- Reinvigorating COTL1Nature cell biology · 2026Article
- Uncoupling tumor immunogenicity from cell death with platinum(IV)-antibody conjugates.National science review · 2026Article
- Upregulation of an Epithelial miRNA Is Associated with Immune Evasion in Progressive Bronchial Premalignant Lesions.Cancer immunology research · 2026Article
- Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- ULK1 drives NDP52-mediated selective autophagic degradation of MHC-I to promote immune evasion in HPV-positive head and neck cancer.bioRxiv : the preprint server for biology · 2026Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 2 countries.
Shengqing Stan Gu *Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Wubing Zhang *Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-2233-299X
Xiaoqing Wang *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Peng Jiang *Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-7828-5486
Nicole TraughDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-1194-8177
Ziyi LiDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Clifford MeyerDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Blair StewigDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yingtian XieCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Xia BuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michael P ManosCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Alba Font-TelloCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Evisa GjiniCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-6951-9279
Ana LakoCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Klothilda LimCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jake ConwayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Alok K TewariDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zexian ZengDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Avinash Das SahuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Collin TokheimDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jason L WeiratherDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-0556-0616
Jingxin FuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-4028-3661
Yi ZhangDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7453-6188
Benjamin KrogerThe University of Texas Southwestern Medical School, Dallas, Texas.ORCID 0000-0001-5675-9102
Jin Hua LiangDepartment of Microbiology, Harvard Medical School, Boston, Massachusetts.
Paloma CejasCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7210-5616
Scott RodigDepartment of Pathologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Henry W LongCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-6849-6629
Benjamin E GewurzDepartment of Microbiology, Harvard Medical School, Boston, Massachusetts.
F Stephen HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Myles BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. xsliu@ds.dfci.harvard.edu myles_brown@dfci.harvard.edu.
X Shirley LiuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts. xsliu@ds.dfci.harvard.edu myles_brown@dfci.harvard.edu.
Dana-Farber Cancer Institute · USHarvard University · USTongji University · CNBrigham and Women's Hospital · USNational Cancer Institute · USThe University of Texas Southwestern Medical Center · US
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2017 to 2021
$10.6MComputational approaches for the analyses of spatial profiling technologiesZIABC011890 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JIANG, PENG · 2019 to 2025
$4.1MRegulators of Cancer Immunotherapy ResponseR01CA234018 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2019 to 2022
$2.3MMetabolic Network Remodeling in Epstein-Barr Virus LymphomagenesisR01AI137337 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2018 to 2022
$2.2MNCI NIH HHS P50 CA101942NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA234018NHGRI NIH HHS T32 HG002295NIAID NIH HHS R01 AI137337
Abstract
Immune checkpoint blockade (ICB) therapy revolutionized cancer treatment, but many patients with impaired MHC-I expression remain refractory. Here, we combined FACS-based genome-wide CRISPR screens with a data-mining approach to identify drugs that can upregulate MHC-I without inducing PD-L1. CRISPR screening identified TRAF3, a suppressor of the NFκB pathway, as a negative regulator of MHC-I but not PD-L1. The
Indexed as
B7-H1 AntigenData MiningGene Expression ProfilingHistocompatibility Antigens Class IHumansImmune Checkpoint InhibitorsImmunotherapyNeoplasmsTumor MicroenvironmentB7-H1 AntigenHistocompatibility Antigens Class IImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.